CompletedPhase 2NCT00003757
Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
Studying Classic hairy cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swiss Cancer Institute
- Principal Investigator
- Albert von Rohr, MD, M.DKlinik Hirslanden, Zurich
- Intervention
- rituximab(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1998 – 2007
Study locations (1)
- Klinik Hirslanden, Zurich, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003757 on ClinicalTrials.govOther trials for Classic hairy cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNANCT06781515Assessment of Disease Burden in Hairy Cell LeukemiaIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNCT06774677Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06764524Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06561360A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06340737AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasStanford University
- RECRUITINGPHASE1NCT04815356Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)